PHOEBE TABARANZA: Open Payments
NPI 1295474468 · SAN DIEGO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$458 in 18 payments from 4 companies in 2025. Trend: 2023 $154 · 2024 $1,084 · 2025 $458
Food & beverage: $458
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC | 9 | $222 |
| GlaxoSmithKline, LLC. | 5 | $148 |
| AstraZeneca Pharmaceuticals LP | 3 | $63 |
| Eisai Inc. | 1 | $26 |
Products named: LYNPARZA, JEMPERLI, Lenvima.
Industry payments across CA — which companies pay providers there.
